<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="341">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156710</url>
  </required_header>
  <id_info>
    <org_study_id>ACT17012</org_study_id>
    <secondary_id>U1111-1267-2612</secondary_id>
    <secondary_id>2021-000010-41</secondary_id>
    <nct_id>NCT05156710</nct_id>
  </id_info>
  <brief_title>BIVV020 in Prevention and Treatment of Antibody-mediated Rejection (AMR)</brief_title>
  <official_title>A Multi-cohort, Randomized, Phase 2, Open-label Study to Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Adult Kidney Transplant Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        -  Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR&#xD;
&#xD;
        -  Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess the overall efficacy of BIVV020 in prevention or treatment of AMR&#xD;
&#xD;
        -  To characterize the safety and tolerability of BIVV020 in kidney transplant participants&#xD;
&#xD;
        -  To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant&#xD;
           participants&#xD;
&#xD;
        -  To evaluate the immunogenicity of BIVV020&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to approximately 2 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2021</start_date>
  <completion_date type="Anticipated">April 9, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 14, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort A: Treatment failure rate</measure>
    <time_frame>Up to Week 49</time_frame>
    <description>Defined as the proportion of participants meeting at least one of the following criteria:&#xD;
Biopsy-proven active AMR as per Banff Criteria 2019 as per central pathology assessment,&#xD;
Graft loss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort B: AMR resolution rate</measure>
    <time_frame>Up to Week 49</time_frame>
    <description>Defined as the proportion of participants with post-treatment biopsy not fulfilling active AMR diagnosis criteria as per Banff Criteria 2019 as per central pathology assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort A: Treatment failure rate per local assessment using Banff criteria 2019</measure>
    <time_frame>Up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: AMR resolution rate per local assessment using Banff criteria 2019</measure>
    <time_frame>Up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal function from baseline per central laboratory assessment of estimated glomerular filtration rate (eGFR) from serum creatinine using Modification of Diet in Renal Disease equation (MDRD)</measure>
    <time_frame>Up to 22 weeks after end of treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal function from baseline per central laboratory assessment using protein: creatinine ratio</measure>
    <time_frame>Up to 22 weeks after end of treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in allograft histopathology Banff score</measure>
    <time_frame>Up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival as predicted by iBOX</measure>
    <time_frame>Up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events (AEs)</measure>
    <time_frame>Up to end of study, up to approximately 2 years</time_frame>
    <description>Number of participants with treatment emergent adverse events (TEAEs)/ serious adverse events (SAES), laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systemic lupus erythematosus (SLE) panel</measure>
    <time_frame>Up to 22 weeks after end of treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma exposure of BIVV020 assessing pharmacokinetic parameter Cmin</measure>
    <time_frame>Up to 22 weeks after end of treatment period</time_frame>
    <description>Cmin is defined as the minimum concentration after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma exposure of BIVV020 assessing pharmacokinetic parameter AUC</measure>
    <time_frame>Up to 22 weeks after end of treatment period</time_frame>
    <description>AUC is defined as the area under plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-BIVV020 antibodies</measure>
    <time_frame>Up to 22 weeks after end of treatment period</time_frame>
    <description>Number of participants developed drug-induced ADAs</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>BIVV020 with Standard of Care (SOC) Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will receive BIVV020 and SOC immunosuppression including induction therapy, tacrolimus, and mycophenolate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SOC) Cohort A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>SOC immunosuppression including induction therapy, tacrolimus, and mycophenolate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIVV020 with Standard of Care (SOC) Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will receive BIVV020 and SOC which includes plasmapheresis, IVIg, corticosteroids, rixutimxab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SOC) Cohort B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>SOC includes plasmapheresis, IVIg, corticosteroids, rixutimxab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIVV020</intervention_name>
    <description>Pharmaceutical Form: Solution for injection Route of Administration: Intravenous</description>
    <arm_group_label>BIVV020 with Standard of Care (SOC) Cohort A</arm_group_label>
    <arm_group_label>BIVV020 with Standard of Care (SOC) Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous immunoglobulin (IVIg)</intervention_name>
    <description>Pharmaceutical Form: Solution for injection Route of Administration: Intravenous</description>
    <arm_group_label>BIVV020 with Standard of Care (SOC) Cohort B</arm_group_label>
    <arm_group_label>Standard of Care (SOC) Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Pharmaceutical Form: Solution for injection Route of Administration: Intravenous</description>
    <arm_group_label>BIVV020 with Standard of Care (SOC) Cohort B</arm_group_label>
    <arm_group_label>Standard of Care (SOC) Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithymocyte globulin (ATG)</intervention_name>
    <description>Pharmaceutical Form: Solution for injection Route of Administration: Intravenous</description>
    <arm_group_label>BIVV020 with Standard of Care (SOC) Cohort A</arm_group_label>
    <arm_group_label>Standard of Care (SOC) Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Pharmaceutical Form: Tablet Route of Administration: Oral</description>
    <arm_group_label>BIVV020 with Standard of Care (SOC) Cohort A</arm_group_label>
    <arm_group_label>Standard of Care (SOC) Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate</intervention_name>
    <description>Pharmaceutical Form: Tablet Route of Administration: Oral</description>
    <arm_group_label>BIVV020 with Standard of Care (SOC) Cohort A</arm_group_label>
    <arm_group_label>Standard of Care (SOC) Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>Pharmaceutical Form: Vary Route of Administration: Vary</description>
    <arm_group_label>BIVV020 with Standard of Care (SOC) Cohort B</arm_group_label>
    <arm_group_label>Standard of Care (SOC) Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Participant intended to receive SOC therapy per Investigator's judgment and local&#xD;
        practice.&#xD;
&#xD;
        Cohort A: Participants with chronic kidney disease who will receive a kidney transplant&#xD;
        from a living or deceased donor to whom they are sensitized, and/or required&#xD;
        desensitization prior to transplantation.&#xD;
&#xD;
        Cohort B: Participants who are kidney transplant recipients diagnosed with active AMR.&#xD;
&#xD;
          -  BMI ≤ 40 kg/m2.&#xD;
&#xD;
          -  Contraceptive use by women during the treatment period, and for at least 49 weeks&#xD;
             after the last administration of IMP (BIVV020 + SOC arm participant) or last treatment&#xD;
             period visit (SOC arm participant).&#xD;
&#xD;
          -  Contraceptive use by men during the treatment period, and for at least 49 weeks after&#xD;
             the last administration of IMP (BIVV020 + SOC arm participant) or last treatment&#xD;
             period visit (SOC arm participant).&#xD;
&#xD;
          -  18-75 years old at the time of consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who are ABO incompatible with their donors.&#xD;
&#xD;
          -  Participants with known active ongoing infection as per below:&#xD;
&#xD;
               1. Positive HIV.&#xD;
&#xD;
               2. Positive HBV.&#xD;
&#xD;
               3. HCV with detectable HCV RNA.&#xD;
&#xD;
               4. Within 4 weeks of first study intervention: any serious infection, or infection&#xD;
                  requiring antibiotic treatment against an identified or suspected bacterial&#xD;
                  pathogen.&#xD;
&#xD;
          -  History of active tuberculosis (TB) regardless of treatment.&#xD;
&#xD;
          -  Participants with clinical diagnosis of systemic lupus erythematosus (SLE).&#xD;
&#xD;
          -  Prior treatment with complement system inhibitor within 5 times the half-life.&#xD;
&#xD;
          -  Current enrollment in any other clinical study where the last investigational study&#xD;
             treatment administration was within 5 half-lives from study intervention initiation.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>December 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 13, 2021</last_update_submitted>
  <last_update_submitted_qc>December 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

